| PAC1, VPAC1, and VPAC2 Receptor Expression in Rat and Human Trigeminal Ganglia: Characterization of PACAP-Responsive Receptor Antibodies. | PAC(1), VPAC(1), and VPAC(2) Receptor Expression in Rat and Human Trigeminal Ganglia: Characterization of PACAP-Responsive Receptor Antibodies.
Tasma Z, Siow A, Harris PWR, Brimble MA, O'Carroll SJ, Hay DL, Walker CS., Free PMC Article | 12/10/2022 |
| [VIPR1 promoter methylation promotes transcription factor AP-2alpha binding to inhibit VIPR1 expression and promote hepatocellular carcinoma cell growth in vitro]. | [VIPR1 promoter methylation promotes transcription factor AP-2α binding to inhibit VIPR1 expression and promote hepatocellular carcinoma cell growth in vitro].
Ning S, He C, Guo Z, Zhang H, Mo Z., Free PMC Article | 07/30/2022 |
| Activation of VIPR1 suppresses hepatocellular carcinoma progression by regulating arginine and pyrimidine metabolism. | Activation of VIPR1 suppresses hepatocellular carcinoma progression by regulating arginine and pyrimidine metabolism.
Fu Y, Liu S, Rodrigues RM, Han Y, Guo C, Zhu Z, He Y, Mackowiak B, Feng D, Gao B, Zeng S, Shen H., Free PMC Article | 07/30/2022 |
| Activation of Th lymphocytes alters pattern expression and cellular location of VIP receptors in healthy donors and early arthritis patients. | Activation of Th lymphocytes alters pattern expression and cellular location of VIP receptors in healthy donors and early arthritis patients.
Villanueva-Romero R, Gutiérrez-Cañas I, Carrión M, González-Álvaro I, Rodríguez-Frade JM, Mellado M, Martínez C, Gomariz RP, Juarranz Y., Free PMC Article | 10/24/2020 |
| Cryo-EM structure of an activated VIP1 receptor-G protein complex revealed by a NanoBiT tethering strategy. | Cryo-EM structure of an activated VIP1 receptor-G protein complex revealed by a NanoBiT tethering strategy.
Duan J, Shen DD, Zhou XE, Bi P, Liu QF, Tan YX, Zhuang YW, Zhang HB, Xu PY, Huang SJ, Ma SS, He XH, Melcher K, Zhang Y, Xu HE, Jiang Y., Free PMC Article | 09/12/2020 |
| 3D structure prediction of VAPC1 and identification of dual natural inhibitors for VPAC1 and EGFR. | 3D structure prediction of VAPC1 and identification of dual natural inhibitors for VPAC1 and EGFR.
Sarkar A, Sen S. | 05/30/2020 |
| follicle-associated epithelium-adjacent villus epithelium in ileum of Crohn's disease possessed more mucosal mast cells and mucosal mast cells expressing VPAC1 but not VPAC2. | Upregulation of intestinal mucosal mast cells expressing VPAC1 in close proximity to vasoactive intestinal polypeptide in inflammatory bowel disease and murine colitis.
Casado-Bedmar M, Heil SDS, Myrelid P, Söderholm JD, Keita ÅV. | 01/25/2020 |
| S. Typhimurium infection exploits host VPAC1/VIP to gain survival advantage in human monocytes. | Immune evasion by Salmonella: exploiting the VPAC1/VIP axis in human monocytes.
Askar B, Higgins J, Barrow P, Foster N., Free PMC Article | 01/25/2020 |
| Enhanced expression of VPAC1 in primary gastric cancer correlates with metastasis and poor prognosis.VPAC1 activation induces Ca2+ signaling to promote migration and invasion of gastric cancer cells. | VPAC1 couples with TRPV4 channel to promote calcium-dependent gastric cancer progression via a novel autocrine mechanism.
Tang B, Wu J, Zhu MX, Sun X, Liu J, Xie R, Dong TX, Xiao Y, Carethers JM, Yang S, Dong H. | 12/7/2019 |
| Findings point out the tumor suppressor roles of VIPR1 in human LUAD pathogenesis. | Mechanism of VIPR1 gene regulating human lung adenocarcinoma H1299 cells.
Zhao L, Yu Z, Zhao B. | 11/9/2019 |
| The promoter region of VIPR1 was methylated and DNA methylation inhibited VIPR1 gene transcription. Deacetylation of H3K27 in the promoter of VIPR1 inhibited the transcription of VIPR1 in hepatocellular carcinoma (HCC). Low expression of VIPR1 had an adverse prognostic impact on HCC, and such expression is at least partially mediated by epigenetic modification. | Promoter methylation and H3K27 deacetylation regulate the transcription of VIPR1 in hepatocellular carcinoma.
Lu S, Lu H, Jin R, Mo Z. | 10/12/2019 |
| In vitro-polarized macrophages by GM-CSF (GM-MO), with a proinflammatory profile, expressed higher levels of VIP receptors, vasoactive intestinal polypeptide receptors 1 and 2 (VPAC1 and VPAC2, respectively), than macrophages polarized by M-CSF (M-MO) with anti-inflammatory activities. RA synovial macrophages, according to their GM-CSF-like polarization state, expressed both VPAC1 and VPAC2. | VIP impairs acquisition of the macrophage proinflammatory polarization profile.
Carrión M, Pérez-García S, Martínez C, Juarranz Y, Estrada-Capetillo L, Puig-Kröger A, Gomariz RP, Gutiérrez-Cañas I. | 09/9/2017 |
| VPAC1 rs9677 CC genotype could be correlated with a reduced response to statin therapy and seems to be involved in diabetes cardiomyopathy in female patients with type 2 diabetes. | The SNP rs9677 of VPAC1 gene is associated with glycolipid control and heart function in female patients with type 2 diabetes: A follow-up study.
Tavaglione F, Filardi T, Fallarino M, Mandosi E, Turinese I, Rossetti M, Lenzi A, Morano S. | 12/17/2016 |
| The results reveal that more severe inflammation, based on high levels of IL-6, is associated with lower expression of VPAC1 and, conversely, with increased expression of VPAC2. | Clinical Relevance of VPAC1 Receptor Expression in Early Arthritis: Association with IL-6 and Disease Activity.
Seoane IV, Ortiz AM, Piris L, Lamana A, Juarranz Y, García-Vicuña R, González-Álvaro I, Gomariz RP, Martínez C., Free PMC Article | 07/30/2016 |
| variations at the 3'UTR of the VPAC-1 gene act synergistically to affect the expression of the luciferase as well as of the GFP reporter genes expressed in HEK293T cells. | Single nucleotide polymorphisms in the 3'UTR of VPAC-1 cooperate in modulating gene expression and impact differently on the interaction with miR525-5p.
Paladini F, Porciello N, Camilli G, Tuncer S, Cocco E, Fiorillo MT, Sorrentino R., Free PMC Article | 04/30/2016 |
| These data suggest that VPAC1 overexpression is associated with poorer differentiation of colon cancer, which is likely caused by subsequent EGFR activation in cancer cells. | VPAC1 overexpression is associated with poor differentiation in colon cancer.
Liu S, Zeng Y, Li Y, Guo W, Liu J, Ouyang N. | 10/11/2014 |
| VIP regulates CFTR membrane expression and function in Calu-3 cells by increasing its interaction with NHERF1 and P-ERM in a VPAC1- and PKCepsilon-dependent manner. | VIP regulates CFTR membrane expression and function in Calu-3 cells by increasing its interaction with NHERF1 and P-ERM in a VPAC1- and PKCε-dependent manner.
Alshafie W, Chappe FG, Li M, Anini Y, Chappe VM. | 08/30/2014 |
| VPAC1 receptor has a role in endotoxemia in peripheral blood mononuclear cells | VPAC1 receptor expression in peripheral blood mononuclear cells in a human endotoxemia model.
Storka A, Burian B, Führlinger G, Clive B, Sun T, Crevenna R, Gsur A, Mosgöller W, Wolzt M., Free PMC Article | 01/4/2014 |
| The overexpression of VPAC1 and VPAC2 receptors and COX-2 in cancer tissue gives them a potential role as targets for diagnosis of prostate cancer. | Overexpression of vasoactive intestinal peptide receptors and cyclooxygenase-2 in human prostate cancer. Analysis of potential prognostic relevance.
Fernández-Martínez AB, Carmena MJ, Arenas MI, Bajo AM, Prieto JC, Sánchez-Chapado M. | 11/17/2012 |
| hree residues play an important role in VPAC1 interaction with the first histidine residue of VIP. These data demonstrate that VIP and PG97-269 bind to distinct domains of VPAC1 | Spatial proximity between the VPAC1 receptor and the amino terminus of agonist and antagonist peptides reveals distinct sites of interaction.
Ceraudo E, Hierso R, Tan YV, Murail S, Rouyer-Fessard C, Nicole P, Robert JC, Jamin N, Neumann JM, Robberecht P, Laburthe M, Couvineau A. | 06/30/2012 |
| The genetic association reported here indicates that VIP/VPAC1 signaling can be a relevant pathway in the pathogenesis of type 2 diabetes in females | Gender-dependent association of type 2 diabetes with the vasoactive intestinal peptide receptor 1.
Paladini F, Adinolfi V, Cocco E, Ciociola E, Tamburrano G, Cascino I, Lucantoni F, Morano S, Sorrentino R. | 03/31/2012 |
| silencing of VPAC1 receptor inhibits vasoactive intestinal peptide effects on both EGF receptor and HER2 transactivation and vascular endothelial growth factor secretion in human breast cancer cells | RNA interference-directed silencing of VPAC1 receptor inhibits VIP effects on both EGFR and HER2 transactivation and VEGF secretion in human breast cancer cells.
Valdehita A, Carmena MJ, Bajo AM, Prieto JC. | 03/10/2012 |
| mRNA expression of the VPAC1 receptor was detected in 51% of the tumor specimens, while the incidence of mRNA expression for VPAC2 was 46%. | Gene expression of vasoactive intestinal peptide receptors in human lung cancer.
Szilasi M, Buglyo A, Treszl A, Kiss L, Schally AV, Halmos G. | 01/14/2012 |
| increased expression in patients with allergic rhinitis | Alterations of vasoactive intestinal polypeptide receptors in allergic rhinitis.
Kim DH, Park IH, Cho JS, Lee YM, Choi H, Lee HM. | 12/3/2011 |
| The VIPR1 polymorphism, previously linked to gastrointestinal dysmotility disorders, does not represent a common risk factor for gallstones in the general or in an elderly population. | Analysis of the common vasoactive intestinal peptide receptor 1 polymorphism in gallstone patients.
Krawczyk M, Rusticeanu M, Grünhage F, Mahler M, Portincasa P, Acalovschi M, Lammert F. | 05/28/2011 |